Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
This article was originally published in The Pink Sheet Daily
Executive Summary
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.
You may also be interested in...
GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.
GSK’s Genelabs Acquisition To Focus On Hepatitis C Compounds
Despite the tough capital environment, Genelabs gets $1.30 per share, restoring much of the value its stock lost during 2008.
La Jolla Submits Riquent Application For Lupus In EU
The company is still pursuing a Phase III trial in the U.S. under a Special Protocol Assessment with FDA.